Webster Equity Partners agrees to acquire Lifecore Biomedical
The pending take-private offers $6.28 per share in cash plus a contingent value right tied to milestones.
Lifecore Biomedical has entered a definitive agreement to be acquired by an affiliate of Webster Equity Partners. Shareholders would receive $6.28 per share in cash at closing plus a non-tradable contingent value right tied to specified milestones.
The transaction remains subject to shareholder approval and other closing conditions. Lifecore is a contract development and manufacturing organization focused on injectable drug products.
The agreement includes a 30-day go-shop period during which Lifecore may consider alternative proposals. The companies announced the agreement.
Get Buyout Desk email updates.
Yesterday's platforms, add-ons, recaps, and exits, cleaned up on the site. Email updates are not on a fixed schedule.